I took part in a 2012 psilocybin trial. What I’m seeing now horrifies me,” writes Erica Rex, author of the new book “Seeing ...

Oregon took a leap into the psychedelic unknown when voters approved regulated psilocybin services nearly six years ago to treat addiction, depression and other illnesses. Since then, thousands of ...

In two large-scale trials, Compass Pathways' proprietary form of psilocybin improved people's depression symptoms better than controls.

Updated Part B results demonstrated sustained efficacy for COMP360 psilocybin 25mg, maintaining symptom severity reductions through week 26 after just 1 or 2 doses.

Compass Pathways shares surged Tuesday after the company said its psilocybin therapy for depression met its primarily goals in recent trials. Shares traded 34% higher ahead of the morning bell at ...

Shares of at least four other developers were up by mid-single digits to low-double digits at certain points on Tuesday.

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis. Read more on CMPS stock here.

F OR FIVE years biotech startups have been betting that psychedelic substances could be turned into real medicines. One of them may have hit the jackpot. On February 17th Compass ...

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of ...

A study of mice fed a high-fat/high-fructose diet (designed to induce obesity) found that 12 weeks of treatment with low-dose psilocybin reduced weight gain, symptoms of fatty liver, hyperglycemia, ...

Compass Pathways on Tuesday disclosed results from two Phase 3 studies that support a potential approval of its psilocybin treatment for severe depression, but more detailed data are needed to ...